CStone Pharmaceuticals (HKG:2616) received ethics approval to begin clinical trials of its core candidate CS5007 in Australia, according to a Friday filing with the Hong Kong bourse.
The firm plans to enroll 310 patients in China and Australia to study the cancer treatment's effects.